ERN-EYE Webinar – 5 years gene therapy Luxturna
Date and time
Monday 20th January 2025, 4.30 pm CET.
Programme
- Introduction of the speakers, Pr Katarina Stingl, University Tübingen, Germany.
- What have clinicians learned in 5 years?, Pr Katarina Stingl, University Tübingen, Germany.
- Insights from clinical trials, Pr Bart P. Leroy, Ghent University Hospital, Belgium.
- Can anything be improved in molecular genetics?, Pr Elfride de Baere, Center for Medical Genetics, Ghent University Hospital & Dept of Biomolecular Medicine, Ghent University, Belgium
- Patient perspectives
- Discussion and questions
Registration
Biographies
Katarina Stingl, MD is a professor for Ophthalmology and head of the Center for Rare Eye Diseases and the Clinical Unit for Inherited Retinal Degenerations of the University Tübingen.
Katarina Stingl is an internationally acknowledged expert in clinical and genetic diagnostics of inherited retinal diseases and heads also a research group for multimodal retinal diagnostics in ophthalmology including electrophysiology, retinal imaging, retinal functional evaluations, and metabolic retinal imaging. She works on more than 15 clinical trials for inherited retinal diseases as PI or Co-PI and has years of experience not only in genetic therapies of the retina, but also visual implants, pharmacotherapy and electrostimulation.
Pr Leroy is professor of Ophthalmology, Ophthalmic Genetics and Visual Electrophysiology at Ghent University and the Head of the Ophthalmology department at Ghent University Hospital, Ghent, Belgium.
Pr Leroy completed his medical degree (MD), PhD in medical sciences, residencies in clinical genetics and Ophthalmology and a fellowship in medical retina and visual electrophysiology at Ghent University in Belgium. He also completed a fellowship in medical retina, inherited retinal diseases, visual electrophysiology, and molecular genetics at Moorfields Eye Hospital & Institute of Ophthalmology in London, UK.
Pr Leroy’s focus is diagnosis and detailed clinical phenotyping of inherited retinal degenerations as well as in the development of innovative treatments, including serving as a clinical investigator on therapies for RPE65-IRD and CEP290-IRD. He served as past president for the European Organization for Vision & Eye Research and is a board member of the International Society for Genetic Eye Disease & Retinoblastoma, the Société de la Génétique Ophtalmologique Francophone, and the Belgian Society of Ophthalmology. He is also co-opted board member for ophthalmic genetics of the European Society of Retina Specialists (EURETINA).
Prof. De Baere is Head of Clinic at the CMGG, which offers genetic testing for a wide variety of rare eye diseases such as inherited retinal diseases (IRD), cataract, developmental eye diseases, corneal dystrophies, glaucoma. She chairs the TWG6 ‘Genetic Diagnostics’ of ERN-EYE. She is member of several ocular ClinGen working groups and co-chairs the ABCA4 Variant Curation Expert Panel. She leads the Ophthalmic and Developmental Genetics research team at Ghent University, which is focused on genomics and multi-omics of IRD. She has a special interest in noncoding variation as contributor to missing heritability of IRD and other Mendelian diseases.